Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more
Oscotec Inc (039200) - Net Assets
Latest net assets as of September 2025: ₩122.94 Billion KRW
Based on the latest financial reports, Oscotec Inc (039200) has net assets worth ₩122.94 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩154.14 Billion) and total liabilities (₩31.19 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩122.94 Billion |
| % of Total Assets | 79.76% |
| Annual Growth Rate | 13.43% |
| 5-Year Change | 149.5% |
| 10-Year Change | 391.71% |
| Growth Volatility | 92.67 |
Oscotec Inc - Net Assets Trend (2011–2024)
This chart illustrates how Oscotec Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oscotec Inc (2011–2024)
The table below shows the annual net assets of Oscotec Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩132.36 Billion | +39.74% |
| 2023-12-31 | ₩94.72 Billion | -22.68% |
| 2022-12-31 | ₩122.51 Billion | +324.97% |
| 2021-12-31 | ₩28.83 Billion | -45.66% |
| 2020-12-31 | ₩53.05 Billion | +3.43% |
| 2019-12-31 | ₩51.29 Billion | +10.80% |
| 2018-12-31 | ₩46.29 Billion | +117.92% |
| 2017-12-31 | ₩21.24 Billion | -19.31% |
| 2016-12-31 | ₩26.33 Billion | -2.20% |
| 2015-12-31 | ₩26.92 Billion | +23.57% |
| 2014-12-31 | ₩21.78 Billion | -1.72% |
| 2013-12-31 | ₩22.17 Billion | -9.43% |
| 2012-12-31 | ₩24.47 Billion | -4.87% |
| 2011-12-31 | ₩25.73 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oscotec Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 162451.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩270.62 Billion | 211.83% |
| Total Equity | ₩127.76 Billion | 100.00% |
Oscotec Inc Competitors by Market Cap
The table below lists competitors of Oscotec Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coursera Inc
NYSE:COUR
|
$890.76 Million |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
$890.83 Million |
|
Fortrea Holdings Inc.
NASDAQ:FTRE
|
$891.06 Million |
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
$891.34 Million |
|
CIE Automotive S.A
PINK:CUOTF
|
$890.48 Million |
|
Mesnac Co Ltd
SHE:002073
|
$889.84 Million |
|
Data Patterns (India) Limited
NSE:DATAPATTNS
|
$889.67 Million |
|
Tianjin Guangyu Development Co Ltd
SHE:000537
|
$889.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oscotec Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 98,918,425,620 to 127,755,760,640, a change of 28,837,335,020 (29.2%).
- Net income of 876,526,890 contributed positively to equity growth.
- Share repurchases of 6,583,840,300 reduced equity.
- New share issuances of 52,831,300 increased equity.
- Other factors increased equity by 34,491,817,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩876.53 Million | +0.69% |
| Share Repurchases | ₩6.58 Billion | -5.15% |
| Share Issuances | ₩52.83 Million | +0.04% |
| Other Changes | ₩34.49 Billion | +27.0% |
| Total Change | ₩- | 29.15% |
Book Value vs Market Value Analysis
This analysis compares Oscotec Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 55.38x to 16.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩991.27 | ₩54900.00 | x |
| 2017-12-31 | ₩752.56 | ₩54900.00 | x |
| 2018-12-31 | ₩1590.29 | ₩54900.00 | x |
| 2019-12-31 | ₩1695.71 | ₩54900.00 | x |
| 2020-12-31 | ₩1712.06 | ₩54900.00 | x |
| 2021-12-31 | ₩910.42 | ₩54900.00 | x |
| 2022-12-31 | ₩3334.20 | ₩54900.00 | x |
| 2023-12-31 | ₩2604.22 | ₩54900.00 | x |
| 2024-12-31 | ₩3340.53 | ₩54900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oscotec Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.58%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.34x
- Recent ROE (0.69%) is above the historical average (-19.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -9.58% | -11.82% | 0.47x | 1.72x | ₩-4.13 Billion |
| 2015 | 1.51% | 2.15% | 0.37x | 1.89x | ₩-2.23 Billion |
| 2016 | -13.85% | -102.58% | 0.09x | 1.55x | ₩-6.28 Billion |
| 2017 | -18.33% | -99.61% | 0.10x | 1.91x | ₩-6.02 Billion |
| 2018 | 7.50% | 18.56% | 0.27x | 1.52x | ₩-1.16 Billion |
| 2019 | -43.74% | -513.57% | 0.06x | 1.41x | ₩-27.56 Billion |
| 2020 | -8.21% | -10.02% | 0.57x | 1.44x | ₩-9.66 Billion |
| 2021 | -91.10% | -672.93% | 0.08x | 1.70x | ₩-29.15 Billion |
| 2022 | -19.94% | -482.57% | 0.04x | 1.17x | ₩-36.68 Billion |
| 2023 | -24.54% | -490.40% | 0.04x | 1.34x | ₩-34.17 Billion |
| 2024 | 0.69% | 2.58% | 0.20x | 1.34x | ₩-11.90 Billion |
Industry Comparison
This section compares Oscotec Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $103,681,944,496
- Average return on equity (ROE) among peers: -0.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oscotec Inc (039200) | ₩122.94 Billion | -9.58% | 0.25x | $890.75 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |